Multimodal treatment of Kasabach-Merritt syndrome arising from tufted angioma: A case report

Jiang,Run‑Song; Zhao,Zheng‑Yan

doi:10.3892/ol.2017.6064

Multimodal treatment of Kasabach-Merritt syndrome arising from tufted angioma: A case report

Authors:
- Run‑Song Jiang
- Zheng‑Yan Zhao
View Affiliations

Affiliations: Department of Reconstructive Plastic Surgery, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China
Published online on: April 20, 2017 https://doi.org/10.3892/ol.2017.6064
Pages: 4887-4891

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kasabach-Merritt syndrome (KMS) is a rare type of vascular tumor associated with a severely decreased platelet count. No standard guidelines for the treatment of the disease have been established so far. In the present study, a 1‑year‑old pediatric patient with KMS arising from tufted angioma was successfully and variously treated with steroids, vincristine, surgery and propranolol for 18 months. Systemic steroids stabilized the platelet count stable, while vincristine reduced the size of the tumor. Due to unpredictable response, the patient was operated. Combination of vincristine and propranolol was introduced post‑surgery to improve the severely low platelet count of the patient. Following multimodal therapy for 18 months, there has been no evidence of recurrence or metastasis during 2 years of follow‑up. Currently, the patient is alive and well. The management of KMS presents a challenge, and well‑designed studies are required to clearly determine the benefits and risks of multidisciplinary treatment.

View Figures

View References

1	Kasabach HH and Merritt KK: Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 59:1063–1070. 1940. View Article : Google Scholar
2	Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, Salhi A, Léauté-Labreze C and Kozakewich HP: Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol. 42:225–235. 2000. View Article : Google Scholar : PubMed/NCBI
3	Le Nouail P, Viseux V and Enjolras O: Groupe de Recherche Clinique en Dermatologie Pédiatrique: Kasabach–Merritt phenomenon. Ann Dermatol Venereol. 134:580–586. 2007.(In French). View Article : Google Scholar : PubMed/NCBI
4	O'Rafferty C, O'Regan GM, Irvine AD and Smith OP: Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol. 171:38–51. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ferrandiz-Pulido C, Mollet J, Sabado C, Ferrer B and Garcia-Patos V: Tufted angioma associated with Kasabach-Merritt phenomenon: A therapeutic challenge. Act Derm Venereol. 90:535–537. 2010.
6	Chu CY, Hsiao CH and Chiu HC: Transformation between Kaposiform hemangioendothelioma and tufted angioma. Dermatology. 206:334–337. 2003. View Article : Google Scholar : PubMed/NCBI
7	Nakagawa K: Case report of angioblastoma of the skin. Jpn J Dermatol. 59:92–94. 1949.
8	Jones EW and Orkin M: Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol. 20:214–225. 1989. View Article : Google Scholar : PubMed/NCBI
9	Sadeghpour M, Antaya RJ, Lazova R and Ko CJ: Dilated lymphatic vessels in tufted angioma: A potential source of diagnostic confusion. Am J Dermatopathol. 34:400–403. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hall GW: Kasabach-Merritt syndrome: Pathogenesis and management. Br J Haematol. 112:851–862. 2001. View Article : Google Scholar : PubMed/NCBI
11	Kim T, Roh MR, Cho S and Chung KY: Kasabach-merritt syndrome arising from tufted angioma successfully treated with systemic corticosteroid. Ann Dermatol. 22:426–430. 2010. View Article : Google Scholar : PubMed/NCBI
12	Fahrtash F, McCahon E and Arbuckle S: Successful treatment of kaposiform hemangioendothelioma and tufted angioma with vincristine. J Pediatr Hematol Oncol. 32:506–510. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hermans DJ, van Beynum IM, van der Vijver RJ, Kool LJ, de Blaauw I and van der Vleuten CJ: Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: A new indication for propranolol treatment. J Pediatr Hematol Oncol. 33:e171–e173. 2011. View Article : Google Scholar : PubMed/NCBI
14	Mahendran R, White SI, Clark AH and Sheehan-Dare RA: Response of childhood tufted angioma to the pulsed-dye laser. J Am Acad Dermatol. 47:620–622. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG and Adams DM: Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 57:1018–1024. 2011. View Article : Google Scholar : PubMed/NCBI
16	Rodriguez V, Lee A, Witman PM and Anderson PA: Kasabach-merritt phenomenon: Case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol. 31:522–526. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang Z, Li K, Dong K, Xiao X and Zheng S: Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma and Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 61:1518–1519. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, et al: Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma and Kasabach-Merritt phenomenon. Pediatric Blood Cancer. 59:934–938. 2012. View Article : Google Scholar : PubMed/NCBI
19	Choi JW, Na JI, Hong JS, Kwon SH, Byun SY, Cho KH, Youn SW, Choi HS, Park KD and Park KC: Intractable tufted angioma associated with kasabach-merritt syndrome. Ann Dermatol. 25:129–130. 2013. View Article : Google Scholar : PubMed/NCBI
20	Brunton L, Lazo J and Paker K: Goodman & Gliman's The Pharmacological Basis of Therapeutics. 11th. McGraw-Hill; New York: 2005
21	Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, et al: Kasabach-merritt phenomenon: A retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 24:459–462. 2002. View Article : Google Scholar : PubMed/NCBI
22	Drolet BA, Trenor CC III, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, et al: Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 163:285–291. 2013. View Article : Google Scholar : PubMed/NCBI
23	Hauer J, Graubner U, Konstantopoulous N, Schmidt S, Pfluger T and Schmid I: Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer. 49:852–854. 2007. View Article : Google Scholar : PubMed/NCBI
24	de la Hunt MN: Kasabach-Merritt syndrome: Dangers of interferon and successful treatment with pentoxifylline. J Pediatr Surg. 41:e29–e31. 2006. View Article : Google Scholar : PubMed/NCBI